Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab

Several eczematous eruptions have been described during treatment with anti‐IL17A and anti‐IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL‐17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL‐17A, F and A/F inhibitor.